Molecular Devices Acquires Cytion for $7.5M Plus Stock | GenomeWeb

NEW YORK, July 10 – Molecular Devices has signed a definitive agreement to acquire Cytion, a Swiss developer of drug screening technology, for $7.5 million in cash and 400,000 shares of Molecular Devices stock, Molecular Devices said Tuesday.

Cytion, based in Epalinges, Switzerland, has developed a technique using automated patch clamping for analyzing ion channels, a class of proteins important as drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.